Welcome to our dedicated page for Protagonist Ther SEC filings (Ticker: PTGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Protagonist Therapeutics, Inc. (NASDAQ: PTGX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, giving investors structured access to official information the company submits to the U.S. Securities and Exchange Commission. Protagonist identifies itself in these filings as a biopharmaceutical company with principal executive offices in Newark, California, and uses them to report financial results, corporate updates, and other material events.
Among the key documents available are Form 8-K current reports, which Protagonist files to announce specific developments. Recent 8-K filings referenced in company communications include notices of quarterly financial results and corporate updates, as well as the availability of an updated corporate presentation. These filings typically incorporate press releases as exhibits, providing details on clinical milestones for icotrokinra and rusfertide, collaboration arrangements with Johnson & Johnson and Takeda, and financial metrics.
Investors can also use Protagonist’s SEC filings to follow governance and shareholder matters. For example, a Form 8-K describing the 2025 Annual Meeting of Stockholders outlines the election of directors, advisory votes on executive compensation, and ratification of the independent registered public accounting firm. Such disclosures help readers understand how the company’s board composition and oversight framework are presented to shareholders.
On Stock Titan, these filings are paired with AI-powered summaries that explain the main points of lengthy documents in plain language. When Protagonist files quarterly or annual reports, investors can quickly review how the company characterizes its business, pipeline, collaborations, and risks without reading every page. For current reports on clinical or regulatory milestones, AI summaries highlight the aspects most relevant to PTGX, such as references to icotrokinra’s NDA, rusfertide’s Phase 3 data and NDA submission, or updates to the company’s corporate presentation.
In addition, users can monitor real-time updates from EDGAR so that new Protagonist filings appear promptly as they are posted. Where applicable, Stock Titan also surfaces insider transaction reports (Form 4) and proxy materials, giving a consolidated view of trading by officers and directors, compensation-related votes, and other governance topics. Together, these tools help investors interpret Protagonist’s regulatory record and connect formal disclosures to the company’s clinical and collaboration narrative.
Protagonist Therapeutics outlines a broad late‑ and early‑stage pipeline built on its peptide platform across inflammation, hematology and obesity. Lead asset Icotyde, an oral IL‑23 receptor antagonist licensed to Janssen, has marketing applications filed with the FDA and EMA for moderate‑to‑severe plaque psoriasis, with Janssen guiding to a potential 2026 U.S. launch, subject to approval.
Rusfertide, an injectable hepcidin mimetic for polycythemia vera partnered with Takeda, has an NDA filed in the United States and has Fast Track, Orphan Drug and Breakthrough Therapy designations. Protagonist and Takeda currently share U.S. profits and losses 50/50, and Protagonist expects to exercise a contractual opt‑out in 2026 that would convert this into a global royalty stream.
The company is also advancing PN‑881, an oral IL‑17 antagonist now in Phase 1, an oral hepcidin mimetic PN‑8047, and two obesity candidates, PN‑477 (triple GLP‑1/GIP/glucagon agonist) and PN‑458 (dual GLP‑1/GIP agonist), both with planned oral and injectable formulations. Protagonist ended 2025 with approximately $646.0 million in cash, cash equivalents and marketable securities, up from $559.2 million at year‑end 2024, and remains eligible for substantial future milestones and royalties from its Janssen and Takeda collaborations.
Protagonist Therapeutics reported a challenging 2025 financially but highlighted major regulatory and pipeline milestones. License and collaboration revenue fell to
The company posted a full-year net loss of
Strategically, Protagonist submitted an NDA for rusfertide in
Protagonist ended 2025 with cash, cash equivalents and marketable securities of
Protagonist Therapeutics (PTGX) director Williams Lewis T reported exercising stock options and selling shares. On February 17, 2026, he exercised 18,000 stock options at a price of
That same day, he sold 18,000 common shares in open-market transactions at a weighted average price of
PTGX filed a Form 144 notice for a planned sale of 18,000 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $1,483,495.20 and 62,515,666 shares outstanding. The securities were acquired on February 17, 2026 through a stock option exercise paid in cash on the same date.
RTW Investments, LP and Roderick Wong report beneficial ownership of 5,059,053 shares of Protagonist Therapeutics common stock, representing 8.1% of the class. This percentage is based on 62,515,666 shares outstanding as of October 29, 2025, as disclosed in the company’s Form 10-Q.
The shares are held by RTW-managed funds, with RTW Investments and Dr. Wong sharing voting and dispositive power. They certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Protagonist Therapeutics.
Wellington Management Group LLP and affiliated entities report beneficial ownership of 3,171,423 shares of Protagonist Therapeutics, Inc. common stock, representing 5.07% of the class as of the event date. The firms report no sole voting or dispositive power over these shares.
They disclose shared voting power over 2,542,632 shares and shared dispositive power over 3,171,423 shares, which are held of record by investment-advisory clients. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Protagonist.
Protagonist Therapeutics director William D. Waddill reported an option exercise and share sale on February 6, 2026. He exercised 20,000 stock options at an exercise price of $8.31 per share and acquired 20,000 common shares.
On the same date, he sold 20,000 common shares at a weighted average price of $83.68 per share, in multiple trades between $83.65 and $83.87. After these transactions, he directly owned 7,825 shares of common stock, and the reported stock options were fully exercised with 0 options remaining.
Farallon Capital and affiliated funds report a significant stake in Protagonist Therapeutics, Inc. (PTGX). As of the triggering date, the Farallon funds together hold 6,221,006 common shares and 1,500,000 common stock purchase warrants.
The warrants are subject to a 9.99% beneficial ownership limitation, so only 27,007 warrant shares are currently counted toward ownership, with the remaining 1,472,993 treated as not exercisable within 60 days. Various Farallon entities and individuals each report up to 9.99% beneficial ownership, and the group files on a passive Schedule 13G basis. The amendment also adds Avner A. Husen as a reporting person and removes Richard B. Fried, Rajiv A. Patel, and William Seybold.
PTGX shareholder plans to sell 20,000 shares of common stock under Rule 144 through Morgan Stanley Smith Barney on or about 02/06/2026, with the shares listed on NASDAQ.
The planned sale has an aggregate market value of $1,673,672.00. Shares outstanding were 62,515,666; this is a baseline figure, not the amount being sold. The seller acquired the 20,000 shares the same day by exercising a stock option and paid the purchase price in cash.
The Vanguard Group filed an amended Schedule 13G reporting beneficial ownership of 5,413,690 shares of Protagonist Therapeutics Inc common stock, representing 8.65% of the class as of 12/31/2025.
Vanguard reports shared voting power over 473,004 shares and shared dispositive power over 5,413,690 shares, with no sole voting or dispositive power. The securities are held in the ordinary course of business, and Vanguard states they were not acquired to change or influence control of Protagonist. Vanguard also notes an internal realignment effective January 12, 2026, after which certain subsidiaries may report beneficial ownership separately.